FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Expires: January 31, 2005 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *   FBIO Acquisition, Inc. 2. Date of Event Requiring Statement (Month/Day/Year) 09/12/2016 3. Issuer Name and Ticker or Trading Symbol NATIONAL HOLDINGS CORP [NHLD] (Last) (First) (Middle) 2 GANSEVOORT STREET, 9TH FLOOR 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director __X__ 10% Owner _____ Officer (give title below) _____ Other (specify below) 5. If Amendment, Date Original Filed(Month/Day/Year) (Street) NEW YORK, NY 10014 6. Individual or Joint/Group Filing(Check Applicable Line) ___ Form filed by One Reporting Person _X_ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5) Common Stock 7,037,482 D (1)   Common Stock 371,584 I (2) See footnote (2) Common Stock 89,530 I (3) See footnote (3) Common Stock 44,884 I (4) See footnote (4) Common Stock 16,294 I (5) See footnote (5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
FBIO Acquisition, Inc. 2 GANSEVOORT STREET, 9TH FLOOR NEW YORK, NY 10014	Â	  X	Â	Â
Fortress Biotech, Inc. 2 GANSEVOORT STREET, 9TH FLOOR NEW YORK, NY 10014	Â	  X	Â	Â
Opus Point Partners, LLC 2 GANSEVOORT STREET, 9TH FLOOR NEW YORK, NY 10014	Â	  X	Â	Â
Opus Point Healthcare Innovations (Offshore) Fund Ltd. 2 GANSEVOORT STREET, 9TH FLOOR NEW YORK, NY 10014	Â	  X	Â	Â
WEISS MICHAEL S 2 GANSEVOORT STREET, 9TH FLOOR NEW YORK, NY 10014	  X	  X	Â	Â
ROSENWALD LINDSAY A MD 2 GANSEVOORT STREET, 9TH FLOOR NEW YORK, NY 10014	Â	  X	Â	Â

Signatures

FBIO Acquisition, Inc., By:_/s/ Lindsay A. Rosenwald M.D., Lindsay A. Rosenwald M.D._		09/22/2016
**Signature of Reporting Person		Date
Fortress Biotech, Inc., By: /s/ Lindsay A. Rosenwald M.D., Lindsay A. Rosenwald M.D.		09/22/2016
**Signature of Reporting Person		Date
Opus Point Partners, LLC, By: /s/ Michael S. Weiss, Michael S. Weiss		09/22/2016
**Signature of Reporting Person		Date
Opus Point Healthcare Innovations (Offshore) Fund Ltd., By: /s/ Michael S. Weiss, Michael S. Weiss		09/22/2016
**Signature of Reporting Person		Date
/s/ Michael S. Weiss, Michael S. Weiss		09/22/2016
**Signature of Reporting Person		Date
/s/ Lindsay A. Rosenwald M.D., Lindsay A. Rosenwald M.D._		09/22/2016
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	These securities are owned directly by FBIO Acquisition, Inc. ("FBIO Acquisition"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) FBIO Acquisition, (ii) Fortress Biotech, Inc. ("FBIO"), (iii) Opus Point Partners, LLC ("Opus Point Partners"), (iv) Opus Point Healthcare Innovations (Offshore) Fund Ltd. ("Opus Point Healthcare"), (v) Lindsay A. Rosenwald, M.D. and (vi) Michael S. Weiss (collectively, the "FBIO Group"), and indirectly by FBIO, by its ownership of FBIO Acquisition. Each of the members of the FBIO Group, other than FBIO Acquisition and FBIO, disclaim beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
(2)	These securities are owned directly by Opus Point Partners, and indirectly by Dr. Rosenwald and Mr. Weiss, by their ownership in Opus Point Partners. Each of FBIO Acquisition, FBIO and Opus Point Healthcare disclaim beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
(3)	These securities are owned directly by Opus Point Healthcare, and indirectly by Opus Point Partners and Dr. Rosenwald and Mr. Weiss, by their ownership in Opus Point Partners. Each of FBIO Acquisition and FBIO disclaim beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
(4)	These securities are owned directly by Mr. Weiss. Each of other members of the FBIO Group disclaim beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
(5)	These securities are owned directly by Dr. Rosenwald. Each of other members of the FBIO Group disclaim beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.